Nifty
Sensex
:
:
9871.50
31599.76
-1.10 (-0.01%)
-26.87 (-0.08%)

Pharmaceuticals & Drugs

Rating :
34/99

BSE: 532296 | NSE: GLENMARK

612.45
-2.25 (-0.37%)
26-Sep-2017 | 3:58PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 614.00
  • 619.85
  • 609.00
  • 614.70
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  • 685058
  • 4195.64
  • 994.00
  • 567.80

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 17,307.94
  • 14.21
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 20,975.24
  • 0.33%
  • 3.59

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.53%
  • 2.98%
  • 10.3%
  • FII
  • DII
  • Others
  • 2.89%
  • 2.49%
  • 34.81%

Chart

Price | P:E | P:BV | EV:EBITDA

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 17
Jun 16
Var%
Mar 17
Mar 16
Var%
Dec 16
Dec 15
Var%
Sep 16
Sep 15
Var%
Net Sales
2,363.00
1,943.05
21.61%
2,457.18
2,281.25
7.71%
2,535.01
1,756.37
44.33%
2,224.11
1,874.64
18.64%
Expenses
1,785.55
1,563.98
14.17%
2,013.34
1,978.62
1.75%
1,769.98
1,386.60
27.65%
1,775.34
1,472.75
20.55%
EBITDA
577.45
379.07
52.33%
443.84
302.63
46.66%
765.02
369.76
106.90%
448.77
401.88
11.67%
EBIDTM
24.44%
19.51%
18.06%
13.27%
30.18%
21.05%
20.18%
21.44%
Other Income
15.29
75.92
-79.86%
-51.29
11.69
-
14.57
2.14
580.84%
-1.84
0.80
-
Interest
70.86
43.04
64.64%
69.67
47.50
46.67%
61.74
46.85
31.78%
62.87
42.62
47.51%
Depreciation
77.73
64.23
21.02%
68.90
62.78
9.75%
62.53
55.85
11.96%
68.70
63.38
8.39%
PBT
444.14
347.71
27.73%
173.03
204.04
-15.20%
655.33
269.19
143.45%
315.36
296.68
6.30%
Tax
110.76
120.93
-8.41%
-10.73
32.75
-
178.23
99.25
79.58%
91.77
96.25
-4.65%
PAT
333.38
226.78
47.01%
183.76
171.29
7.28%
477.10
169.94
180.75%
223.58
200.44
11.54%
PATM
14.11%
11.67%
7.48%
7.51%
18.82%
9.68%
10.05%
10.69%
EPS
11.81
8.04
46.89%
6.51
6.08
7.07%
16.91
6.02
180.90%
7.92
7.10
11.55%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Net Sales
9,079.41
7,561.67
6,680.94
5,944.95
4,969.14
4,020.64
2,949.07
2,480.46
2,086.48
1,975.71
Net Sales Growth
20.07%
13.18%
12.38%
19.64%
23.59%
36.34%
18.89%
18.88%
5.61%
 
Cost Of Goods Sold
2,552.03
2,246.58
1,538.25
1,785.62
1,584.70
1,291.00
951.07
784.28
658.07
472.22
Gross Profit
6,527.39
5,315.09
5,142.69
4,159.33
3,384.44
2,729.65
1,998.00
1,696.18
1,428.41
1,503.48
GP Margin
71.89%
70.29%
76.98%
69.96%
68.11%
67.89%
67.75%
68.38%
68.46%
76.10%
Total Expenditure
7,042.71
6,124.52
5,466.62
4,854.17
3,953.86
3,306.28
2,356.82
1,860.89
1,631.50
1,175.18
Power & Fuel Cost
127.02
120.47
109.11
93.50
80.13
0.00
0.00
31.86
25.55
19.48
% Of Sales
1.40%
1.59%
1.63%
1.57%
1.61%
0%
0%
1.28%
1.22%
0.99%
Employee Cost
1,640.81
1,378.19
1,212.61
1,026.15
782.95
628.89
510.17
289.95
272.34
173.54
% Of Sales
18.07%
18.23%
18.15%
17.26%
15.76%
15.64%
17.30%
11.69%
13.05%
8.78%
Manufacturing Exp.
1,044.48
956.59
1,323.66
336.59
272.53
54.40
40.76
142.80
156.13
154.22
% Of Sales
11.50%
12.65%
19.81%
5.66%
5.48%
1.35%
1.38%
5.76%
7.48%
7.81%
General & Admin Exp.
525.16
491.20
253.29
859.67
678.94
1,331.99
854.82
268.51
258.24
175.40
% Of Sales
5.78%
6.50%
3.79%
14.46%
13.66%
33.13%
28.99%
10.83%
12.38%
8.88%
Selling & Distn. Exp.
1,064.70
892.67
991.23
524.25
521.00
0.00
0.00
310.32
254.38
171.85
% Of Sales
11.73%
11.81%
14.84%
8.82%
10.48%
0%
0%
12.51%
12.19%
8.70%
Miscellaneous Exp.
88.52
38.82
38.48
228.40
33.61
0.00
0.00
33.15
6.79
171.85
% Of Sales
0.97%
0.51%
0.58%
3.84%
0.68%
0%
0%
1.34%
0.33%
0.43%
EBITDA
2,036.70
1,437.15
1,214.32
1,090.78
1,015.28
714.36
592.25
619.57
454.98
800.53
EBITDA Margin
22.43%
19.01%
18.18%
18.35%
20.43%
17.77%
20.08%
24.98%
21.81%
40.52%
Other Income
37.37
20.00
6.88
11.48
10.75
18.17
144.41
50.45
179.26
53.69
Interest
237.32
178.88
190.15
188.59
160.01
146.57
160.46
165.50
145.72
71.04
Depreciation
264.37
234.28
300.41
216.79
127.01
97.88
94.68
120.61
102.68
71.68
PBT
1,572.38
1,043.98
730.63
696.88
739.00
488.09
481.54
383.90
385.84
711.50
Tax
382.68
300.94
334.07
151.27
110.72
23.78
23.70
52.87
75.41
79.39
Tax Rate
25.66%
28.83%
61.46%
21.71%
14.98%
4.87%
4.92%
13.77%
28.04%
11.16%
PAT
1,108.80
743.23
209.54
542.27
620.03
460.35
453.20
324.47
191.66
632.13
PAT before Minority Interest
1,108.75
743.04
209.47
545.60
628.29
464.31
457.83
331.03
193.47
632.11
Minority Interest
0.05
0.19
0.07
-3.33
-8.26
-3.96
-4.63
-6.56
-1.81
0.02
PAT Margin
12.21%
9.83%
3.14%
9.12%
12.48%
11.45%
15.37%
13.08%
9.19%
32.00%
PAT Growth
49.19%
254.70%
-61.36%
-12.54%
34.69%
1.58%
39.67%
69.29%
-69.68%
 
Unadjusted EPS
39.29
26.47
7.72
20.01
22.91
17.03
16.78
12.40
7.70
25.80

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Shareholder's Funds
4,492.52
3,629.64
1,783.49
2,983.28
2,763.03
2,401.63
2,037.24
2,355.23
1,598.16
1,517.87
Share Capital
28.22
28.22
27.13
27.12
27.09
27.05
27.03
26.98
25.05
24.87
Total Reserves
4,462.86
3,599.98
1,756.36
2,956.16
2,735.94
2,374.58
2,010.21
2,328.25
1,573.10
1,493.00
Non-Current Liabilities
3,257.81
1,499.40
2,749.09
1,966.58
1,625.13
1,137.64
519.01
1,940.41
2,151.27
1,085.49
Secured Loans
0.00
0.00
0.00
2,428.66
1,920.30
1,312.47
617.07
241.41
382.65
196.13
Unsecured Loans
4,536.34
2,487.30
2,574.38
0.00
0.00
0.00
0.00
1,627.98
1,711.69
794.81
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
14.58
6.90
0.00
0.00
0.00
Current Liabilities
2,702.68
3,999.25
3,776.71
2,949.17
2,201.39
1,901.74
2,259.06
518.62
456.33
320.72
Trade Payables
1,903.52
1,940.79
1,948.04
1,362.58
1,036.94
788.83
657.41
379.27
343.48
230.79
Other Current Liabilities
509.32
1,137.01
1,264.30
973.31
763.41
414.83
109.80
119.38
96.41
72.17
Short Term Borrowings
187.19
787.42
347.60
353.32
367.82
687.46
1,480.23
0.00
0.00
0.00
Short Term Provisions
102.65
134.03
216.78
259.95
33.22
10.63
11.62
19.97
16.44
17.76
Total Liabilities
10,452.59
9,127.99
8,309.10
7,912.31
6,613.91
5,466.01
4,842.01
4,827.27
4,208.92
2,925.56
Net Block
2,755.09
2,593.55
2,015.38
2,889.66
2,406.26
2,237.30
2,066.62
1,787.31
1,566.24
918.51
Gross Block
4,769.92
4,300.54
3,495.47
3,632.62
2,934.90
2,650.96
2,383.39
2,175.54
1,838.58
1,124.10
Accumulated Depreciation
2,014.83
1,706.99
1,480.09
742.96
528.63
413.66
316.77
388.23
272.33
205.59
Non Current Assets
3,577.96
3,223.69
2,978.04
3,149.61
2,887.10
2,518.85
2,243.24
2,406.20
2,129.78
1,274.56
Capital Work in Progress
708.11
542.79
477.13
206.24
422.31
248.33
145.70
600.77
545.41
337.23
Non Current Investment
15.69
17.20
17.12
0.00
0.00
0.00
0.00
18.12
18.12
18.82
Long Term Loans & Adv.
98.94
69.99
468.16
33.39
36.52
0.00
0.00
0.00
0.00
0.00
Other Non Current Assets
0.13
0.16
0.27
20.33
22.00
33.23
30.92
0.00
0.00
0.00
Current Assets
6,874.64
5,904.30
5,331.06
4,762.69
3,726.81
2,947.15
2,598.77
2,421.07
2,079.14
1,651.00
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
2,139.05
1,567.76
1,269.04
932.88
843.53
787.67
807.01
708.46
630.23
400.74
Sundry Debtors
2,404.32
2,492.65
2,511.76
2,156.34
1,640.05
1,243.61
1,130.81
1,078.28
955.34
806.85
Cash & Bank
1,056.36
857.12
775.88
800.67
607.31
321.92
195.83
107.02
71.48
156.51
Other Current Assets
1,274.90
391.88
31.44
104.37
635.91
593.95
465.11
527.31
422.09
286.90
Short Term Loans & Adv.
775.74
594.89
742.94
768.44
540.03
518.90
322.39
527.31
422.09
286.90
Net Current Assets
4,171.96
1,905.05
1,554.35
1,813.53
1,525.42
1,045.41
339.71
1,902.45
1,622.81
1,330.28
Total Assets
10,452.60
9,127.99
8,309.10
7,912.30
6,613.91
5,466.00
4,842.01
4,827.27
4,208.92
2,925.56

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Cash From Operating Activity
657.43
344.85
481.68
853.73
647.93
804.39
930.58
352.40
15.91
371.78
PBT
1,491.43
1,043.98
543.54
696.88
739.00
488.09
481.55
383.90
268.88
711.50
Adjustment
726.56
391.03
522.76
709.78
342.45
484.05
189.65
265.26
274.15
133.39
Changes in Working Capital
-861.51
-611.96
-266.82
-290.07
-268.49
-34.79
353.13
-209.36
-387.66
-384.56
Cash after chg. in Working capital
1,356.48
823.05
799.49
1,116.58
812.96
937.35
1,024.34
439.80
155.37
460.33
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-699.05
-478.20
-317.81
-262.86
-165.03
-132.96
-93.75
-87.40
-139.46
-88.55
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-712.35
-880.17
-540.04
-368.10
-464.06
-277.79
-367.27
-386.91
-950.16
-509.62
Net Fixed Assets
-256.09
-286.93
-1,354.84
-112.12
-178.05
-54.88
-40.77
-52.58
406.38
-188.35
Net Investments
-8.28
-198.90
-250.28
-114.91
-211.06
-42.02
-48.33
-755.29
-40.93
-57.60
Others
-447.98
-394.34
1,065.08
-141.07
-74.95
-180.89
-278.17
420.96
-1,315.61
-263.67
Cash from Financing Activity
543.15
698.60
199.22
-98.02
195.24
-361.39
-435.61
70.05
849.23
188.58
Net Cash Inflow / Outflow
488.24
163.27
140.86
387.61
379.11
165.21
127.70
35.54
-85.02
50.75
Opening Cash & Equivalents
857.12
763.74
794.80
605.18
320.08
194.87
103.58
71.48
156.51
105.75
Closing Cash & Equivalent
1,056.36
857.12
763.74
794.80
605.18
320.08
194.87
107.02
71.48
156.51

Financial Ratios

Consolidated /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Book Value (Rs.)
159.16
108.32
65.74
109.99
102.01
88.77
75.38
87.28
63.79
61.03
ROA
11.33%
8.01%
2.58%
7.51%
10.40%
9.01%
9.47%
7.33%
5.42%
26.01%
ROE
27.31%
29.75%
8.79%
18.99%
24.33%
20.92%
20.85%
16.75%
12.42%
57.35%
ROCE
20.54%
19.04%
12.40%
15.04%
17.67%
14.44%
15.34%
13.88%
13.37%
37.88%
Fixed Asset Turnover
2.03
2.00
1.90
1.83
1.79
1.60
1.29
1.25
1.43
2.19
Receivable days
97.29
116.95
125.97
115.37
104.99
107.78
136.71
148.42
151.98
124.70
Inventory Days
73.65
66.29
59.42
53.99
59.39
72.38
93.78
97.70
88.92
60.90
Payable days
98.59
109.46
95.22
83.15
68.48
108.47
106.73
68.48
62.10
61.26
Cash Conversion Cycle
72.35
73.78
90.17
86.21
95.91
71.69
123.76
177.63
178.80
124.34
Total Debt/Equity
1.05
1.30
2.13
1.10
1.00
0.93
1.03
0.79
1.31
0.65
Interest Cover
7.28
6.72
3.86
4.70
5.62
4.33
4.00
3.32
2.85
11.02

News Update


  • Glenmark Pharma expects generics to drive growth in coming years
    25th Sep 2017, 10:04 AM

    Speciality and innovative products will comprise 30 per cent of its revenues by 2025.

    Read More
  • Glenmark receives USFDA approval for Nitroglycerin Sublingual Tablets
    20th Sep 2017, 09:10 AM

    The Nitrostat Sublingual Tablets, 0.3 mg, 0.4 mg, and 0.6 mg market achieved annual sales of approximately $112.7 million

    Read More
  • Glenmark Pharmaceuticals planning to file close to 20-25 ANDAs each year
    19th Sep 2017, 09:55 AM

    The company is planning to file it over the next five years and launch 10-20 products annually

    Read More
  • Glenmark receives final approval from USFDA for Desonide Ointment
    19th Sep 2017, 09:03 AM

    The Desonide Ointment, 0.05% market achieved annual sales of approximately $23.4 million

    Read More
  • Glenmark receives ANDA approval for generic version of Rythmol SR Capsules
    11th Sep 2017, 09:01 AM

    The Rythmol SR Capsules, 225 mg, 325 mg, and 425 mg market achieved annual sales of approximately $69.2 million

    Read More
  • Glenmark receives ANDA approval for Triamcinolone Acetonide Ointment
    23rd Aug 2017, 09:08 AM

    Triamcinolone Acetonide Ointment is the generic version of Kenalog Ointment, 0.1%, of Mylan Pharmaceuticals Inc

    Read More
  • Glenmark receives final approval for generic Zovirax Ointment
    2nd Aug 2017, 09:10 AM

    The Zovirax Ointment, 5% market achieved annual sales of approximately $110.3 million

    Read More
  • Glenmark reports positive data in Phase 2a study of ‘GBR 830’
    1st Aug 2017, 09:10 AM

    GBR 830 is an investigational, anti-OX40 monoclonal antibody, in AD, a common and serious chronic skin disease

    Read More
  • Glenmark Pharma - Quarterly Results
    27th Jul 2017, 12:00 AM

    Read More
  • Glenmark receives final approval from USFDA for Desonide Cream
    25th Jul 2017, 09:25 AM

    The Desonide Cream, 0.05% market achieved annual sales of approximately $44.6 million

    Read More
  • Glenmark Pharmaceuticals enters into exclusive agreement with Cyndea Pharma
    19th Jul 2017, 08:51 AM

    The development, license, manufacture and commercial supply agreement is for Generic Soft-Gelatin Capsule Drug Products

    Read More
  • Glenmark receives USFDA approval for generic version of Azor Tablets
    7th Jul 2017, 09:05 AM

    The Azor Tablets market achieved annual sales of approximately $211.6 million for 12 month period ending May 2017

    Read More
  • Glenmark receives final approval by MHRA for Maloff Protect
    4th Jul 2017, 09:07 AM

    Maloff Protect (250mg/100mg atovaquone/proguanil film-coated tablets) is the first OTC approval granted by the MHRA

    Read More
  • Glenmark receives ANDA approval for Indomethacin Extended-Release Capsules
    27th Jun 2017, 09:06 AM

    Indomethacin Extended-Release Capsules USP, 75 mg is the generic version of Indocin SR Extended-Release Capsules, 75 mg of Iroko Pharmaceuticals LLC

    Read More
  • Glenmark receives tentative ANDA approval for generic Vesicare Tablets
    22nd Jun 2017, 09:02 AM

    The Vesicare Tablets, 5 mg and 10 mg market achieved annual sales of approximately $1.1 billion

    Read More
  • Glenmark enters into licensing agreement with APC Therapeutics
    21st Jun 2017, 09:03 AM

    Glenmark will license the product from APC Therapeutics, and manage all clinical development including regulatory filings and commercialization worldwide

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.